Hydroxytyrosol–AKBA Composition for Selective Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation, such as osteoarthritis, often have adverse side effects and fail to regulate excessive reactive oxygen species and cell death induced by TNF-α without blocking its positive physiological functions.
Innovation Solution
A synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid (AKBA) is administered orally to modulate inflammation and reduce damage to connective tissues by targeting inflammatory mediators like TNF-α, PGE2, and ROS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments for chronic inflammation are administered, then inflammatory symptoms are reduced, but adverse side effects occur and positive physiological functions of TNF-α are blocked
Solution Approach 1:
The patent changes the chemical parameters by using a specific combination of hydroxytyrosol (0.1-10 μM) and AKBA (0.01-1 μM) at optimized concentrations and ratios, achieving selective modulation of inflammatory pathways without the broad suppression of current anti-inflammatory treatments
Solution Approach 2:
The patent employs a composite approach by combining two distinct compounds (hydroxytyrosol and AKBA) that work synergistically through different mechanisms - hydroxytyrosol primarily scavenges ROS while AKBA inhibits 5-LOX and MMPs, achieving enhanced anti-inflammatory效果 with reduced side effects compared to single-agent therapies
2Object-affected harmful factors
If TNF-α is blocked to reduce inflammation, then inflammatory mediators are reduced, but positive physiological functions are lost
Solution Approach 1:
The patent applies local quality by selectively targeting specific inflammatory pathways (5-LOX, MMPs, ROS) rather than broadly suppressing all TNF-α functions, allowing anti-inflammatory effects on harmful mediators while preserving positive physiological functions through pathway-specific modulation
Solution Approach 2:
The patent uses hydroxytyrosol and AKBA as intermediary compounds that indirectly modulate inflammation through multiple mechanisms (ROS scavenging, 5-LOX inhibition, MMP inhibition) rather than directly blocking TNF-α, thereby achieving anti-inflammatory effects while preserving physiological functions
3Object-affected harmful factors
If excessive reactive oxygen species are reduced, then tissue damage is reduced, but treatment selectivity is compromised
Solution Approach 1:
The patent segments the anti-inflammatory approach into multiple independent mechanisms: hydroxytyrosol primarily addresses ROS scavenging while AKBA handles 5-LOX inhibition and MMP suppression, allowing selective targeting of different inflammatory pathways including excessive ROS without compromising overall treatment selectivity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions are described including a synergistic combination of hydroxytyrosol and 3-0-acetyl-11-keto-β-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-0-acetyl-11-keto-β-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.